HOME >> BIOLOGY >> NEWS
JCI Table of Contents, March 14, 2003

ard@cochin.inserm.fr">boitard@cochin.inserm.fr

View the PDF of this article at: https://www.the-jci.org/press/16584.pdf

Cathepsin S promotes atherosclerosis

Remodeling of the ECM contributes to atherosclerosis at multiple stages, and several lines of evidence have implicated the elastolytic cathepsins S (Cat S) and K. Seeking direct evidence for a role of Cat S, Guo-Ping Shi and colleagues crossed mice lacking Cat S with atherosclerosis-prone LDL receptordeficient mice. They found (pages 897906) that the double mutants -- when fed a high-cholesterol diet -- had an attenuated response: atherosclerosis was reduced by more than 50% after 12 weeks on an atherogenic diet, and by 30% after 26 weeks. While this study does not reveal the mechanism by which Cat S contributes to atherogenesis, it does suggest several possible modes of action and underscores the possibility that Cat S may serve as a therapeutic target in arterial diseases.

CONTACT:
Guo-Ping Shi
University of California, San Francisco
Surge 203, Box 0911
90 Medical Center Way
San Francisco, CA 94143
USA
Phone 1-415-514-1208
Fax 1-415-476-9749
E-mail: gpshi@itsa.ucsf.edu

View the PDF of this article at: https://www.the-jci.org/press/14915.pdf

Stem cells mobilized by crisis

Sickle cell disease affects 150 million people worldwide. The only curative therapy is hematopoietic stem cell transplantation. Because of the limited number of matched donors and the toxicity associated with allogeneic transplants, various gene therapy approaches in autologous stem cells are under development. Encouraged by the observation that sickle cell patients have increased numbers of cells expressing stem
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Mar-2003


Page: 1 2 3 4 5 6 7

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, May 1, 2003
9. JCI Table of Contents, April 1, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems everyone ... and culture intertwine to create an expressive and dynamic community ... this energy and contribute to it. With ... Hair Fairies seeks to carry on that tradition with ... Atlanta salon is the newest of 13 ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today ... at the Annual Biocom Global Life Science Partnering Conference.  ... 11:15 AM, at the Torrey Pines Lodge, in San ... organizers at Biocom who have chosen our company, amongst ... biotechnology companies, investors, and clinical researchers," said Mr. Chen. ...
Breaking Biology Technology:
Cached News: